Alkermes (ALKS)

Company Description

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio.

 

COMPANY ADDRESS
852 Winter Street
Waltham, MA 02451
United States

COMPANY PHONE
781-609-6000

COMPANY WEBSITE


Get BioInvest's perspective on Alkermes' CEO

Latest Company News

Norges Bank Buys Shares of 796569 Alkermes Plc (ALKS) The Cerbat Gem - Mar 23, 2017 Alkermes Plc logo Norges Bank bought a new position in Alkermes Plc (NASDAQ:ALKS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The Alkermes Plc (ALKS) Given Positive Rating at Cowen and Company - Petro Global News 24 Analyst Activity – Cowen and Company Reiterates Positive on Alkermes Plc ... - Market Exclusive [...]
Thu, Mar 23, 2017 4:30:00 PM, Continue reading at the source
Alkermes plc (ALKS) to Present Data on Two-Month Dosing Option of ARISTADA at ... StreetInsider.com - Mar 20, 2017 Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress ... [...]
Mon, Mar 20, 2017 11:20:00 AM, Continue reading at the source
Analyst Activity – Cantor Fitzgerald Reiterates Hold on Alkermes Plc (NASDAQ:ALKS) Market Exclusive - Mar 16, 2017 Today, Cantor Fitzgerald reiterated its Hold rating on Alkermes Plc (NASDAQ:ALKS) with a price target of $51.00. There are 3 hold ratings, 7 buy ratings on the stock. The Alkermes Plc (ALKS) Receives “Hold” Rating from Cantor Fitzgerald - Petro Global News 24 [...]
Thu, Mar 16, 2017 7:52:00 PM, Continue reading at the source
Alkermes plc (ALKS) Initiates Phase 3 Gastrointestinal Tolerability Study of ... StreetInsider.com - Mar 16, 2017 Alkermes plc (NASDAQ: ALKS) today announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms of multiple sclerosis (MS). [...]
Thu, Mar 16, 2017 11:03:00 AM, Continue reading at the source
Investors Are Missing An Opportunity With Alkermes Seeking Alpha - Feb 27, 2017 We remain bullish on Alkermes (NASDAQ: ALKS) because of their substantial and growing revenue and their healthy pipeline of valuable assets. Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 37 - Business Wire (press release) Bullish Sweepers and Large Money Flow Witnessed in Alkermes plc (ALKS) - Highland Mirror [...]
Mon, Feb 27, 2017 7:52:00 PM, Continue reading at the source
Alkermes Plc (ALKS) Q4 2016 Results - Earnings Call Transcript Seeking Alpha - Feb 15, 2017 Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today. Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and ... - Business Wire (press release) Marshall Wace LLP Raises Stake in Alkermes PLC (ALKS) - Community Financial News [...]
Wed, Feb 15, 2017 6:10:00 PM, Continue reading at the source
Cantor Fitzgerald Reaffirms Neutral Rating for Alkermes Plc (ALKS) BNB Daily (blog) - Feb 3, 2017 Alkermes Plc logo Cantor Fitzgerald reissued their neutral rating on shares of Alkermes Plc (NASDAQ:ALKS) in a report released on Thursday. [...]
Fri, Feb 03, 2017 1:30:00 AM, Continue reading at the source
Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward Motley Fool - Nov 7, 2016 Alkermes (NASDAQ:ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline. [...]
Mon, Nov 07, 2016 7:42:00 PM, Continue reading at the source
Why Alkermes PLC Skyrocketed Today Motley Fool - Oct 21, 2016 Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo. Analysts Change Price Targets for Two Biotech Stocks: Alkermes Plc (ALKS ... - Smarter Analyst Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD - StreetInsider.com [...]
Fri, Oct 21, 2016 5:26:00 PM, Continue reading at the source
Alkermes Plc (ALKS) Richard Pops on Q2 2016 Results - Earnings Call Transcript Seeking Alpha - Jul 28, 2016 Good morning ladies and gentlemen, and thank you for standing by. Welcome to the Alkermes Conference Call to discuss the Company's Second Quarter Financial Results. Alkermes plc Reports Second Quarter 2016 Financial Results - Business Wire (press release) Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook - Zacks.com [...]
Thu, Jul 28, 2016 5:03:00 PM, Continue reading at the source